Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Acquires Canopy Biosciences

NEW YORK — Bruker said on Friday that it has acquired Canopy Biosciences in a bid to expand its portfolio of targeted multi-omics and fluorescence-based imaging technologies.

Founded in 2016, Canopy provides a range of products and services for gene editing, gene expression analysis and regulation, and bioprocessing including custom cell-line engineering. The St. Louis-based company has also developed a multi-omic platform for immune profiling that includes DNA and RNA sequencing, as well as multiplexed protein detection based on the ChipCytometry technology it acquired through its purchase of German cytometry firm Zellkraftwerk last year.

Financial terms of the transaction were not disclosed.

"We are excited to add the multi-omics and high-content cytometry expertise of Canopy and its novel ChipCytometry platform to Bruker," Mark Munch, president of Bruker's Nano group, said in a statement. "Canopy has a unique set of products that enable single cell, tissue, and suspended cell-based discovery and validation in immunology and targeted proteomics, as well as a suite of complementary multi-omics services."

Last month, Billerica, Massachusetts-based Bruker reported a 13 percent drop in second quarter revenues, however its life science mass spectrometry business was strong.